FDA’s Decision on Zyn Nicotine Pouches: A Closer Look

The FDA has authorized Zyn nicotine pouches to be marketed as a lower risk alternative to cigarettes. These pouches, available in flavors like ‘Cool Mint,’ ‘Smooth,’ and ‘Chill,’ are discreet and addictive. A pouch, comprising bleach-white fibers and nicotine crystals, is placed between the lip and gum, releasing nicotine and chemicals into the bloodstream. This allows users to consume nicotine without drawing attention.

Bret Koplow, acting director at the FDA’s Center for Tobacco Products, stated the decision aims to provide adult users with science-based information about the harms of tobacco products, helping them make informed choices. Some public health researchers believe Zyn is a safer option compared to cigarettes. They argue it could help reduce the 480,000 annual tobacco-related deaths in the U.S. However, some experts warn Zyn might lead to riskier nicotine habits like smoking, especially among young users.

The Case for Zyn

Nicotine, usually derived from the tobacco plant, is used in various products. While some companies employ lab-made nicotine, advocates of nicotine pouches stress their relative safety compared to tobacco products that are burned. Mitch Zeller, a professor at Dartmouth Geisel School of Medicine, highlights the reduced harm associated with nicotine pouches versus smoking cigarettes. He says for persistent smokers, switching to nicotine pouches is an obvious choice.

Brian Erkkila, director of external affairs at Zyn’s parent company Philip Morris International, mentioned Zyn aided his cigarette cessation. He ponders whether his father, who passed from lung cancer, might have benefited had Zyn been available earlier. Despite their benefits, Erkkila acknowledges that nicotine is addictive and not without risk.

Bonnie Halpern-Felsher, a pediatric professor at Stanford University, agrees nicotine pouches have harm reduction potential for smokers. However, she warns they could induce heart problems, neurological issues, psychiatric conditions, or dental issues. There is insufficient data to assess their impact on oral cancer risk. Many effects of nicotine products remain uncertain given their newness.

Concerns and Marketing Strategies

Dr. Robert Jackler, a Stanford University professor emeritus, notes nicotine pouches are not approved cessation tools like gum or patches. He criticizes Zyn’s marketing strategies, which include promoting flavored products and associating them with active lifestyles. He argues Zyn uses terms like ‘cool,’ ‘smooth,’ and ‘chill’ to bolster its appeal as a lifestyle enhancer.

Erkkila responded by emphasizing Philip Morris International’s commitment to marketing responsibly to adults. He claims a 3 mg Zyn delivers comparable nicotine to a cigarette, while 11 mg isn’t considered high. The FDA authorization in 2025 credited flavors with aiding adult smokers in switching to Zyn.

Mary Hrywna, a Rutgers public health professor, agrees flavors aid adult users in transitioning to nicotine pouches. However, she warns against their use by minors, noting risks outweigh benefits for young users.

Adolescent Use and Risks

From 2024 to 2025, 12th graders reported an increase in lifetime nicotine pouch use, rising from 6.8% to 10% as per the University of Michigan’s Monitoring the Future study. Additionally, 4.4% admitted to using nicotine pouches recently. This surge in adolescent experimentation has raised concerns among experts.

Emily Hilliard, a senior press secretary for the Department of Health and Human Services, reiterated FDA’s commitment to preventing youth access to tobacco products, which requires a minimum age of 21 for purchases. Halpern-Felsher reports schools are struggling to manage nicotine pouch use. Her lab provides educational resources on oral tobacco risks.

Hrywna stresses nicotine’s impact on brain development, advocating against adolescent use. Jackler emphasizes the dangers by stating, ‘Don’t start. Don’t get hooked. The suffering is too great.’